Next Science Limited, a medical technology company, researches, develops, and commercializes technologies to eradicate issues in human health caused by biofilms.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$1.26|
|52 Week High||AU$1.10|
|52 Week Low||AU$2.06|
|1 Month Change||-8.70%|
|3 Month Change||-23.17%|
|1 Year Change||3.70%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-6.67%|
Recent News & Updates
|NXS||AU Medical Equipment||AU Market|
Return vs Industry: NXS exceeded the Australian Medical Equipment industry which returned -6.5% over the past year.
Return vs Market: NXS underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: NXS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: NXS's weekly volatility (6%) has been stable over the past year.
About the Company
Next Science Limited, a medical technology company, researches, develops, and commercializes technologies to eradicate issues in human health caused by biofilms. The company develops its products using its Xbio Technology platform. It offers SURGX, an antimicrobial gel designed to reduce surgical site and post-surgical infections; and BACTISURE, a surgical lavage that is used to wash out the surgery site and Intramedullary canal.
Next Science Fundamentals Summary
|NXS fundamental statistics|
Is NXS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NXS income statement (TTM)|
|Cost of Revenue||US$1.23m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Oct 28, 2021
|Earnings per share (EPS)||-0.048|
|Net Profit Margin||-149.42%|
How did NXS perform over the long term?See historical performance and comparison
Is Next Science undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NXS (A$1.26) is trading below our estimate of fair value (A$5.75)
Significantly Below Fair Value: NXS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NXS is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.
PE vs Market: NXS is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NXS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NXS is overvalued based on its PB Ratio (11.6x) compared to the AU Medical Equipment industry average (5x).
How is Next Science forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NXS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NXS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NXS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NXS's revenue (65.6% per year) is forecast to grow faster than the Australian market (5.4% per year).
High Growth Revenue: NXS's revenue (65.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NXS is forecast to be unprofitable in 3 years.
How has Next Science performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NXS is currently unprofitable.
Growing Profit Margin: NXS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NXS is unprofitable, and losses have increased over the past 5 years at a rate of 14.9% per year.
Accelerating Growth: Unable to compare NXS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NXS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: NXS has a negative Return on Equity (-58.6%), as it is currently unprofitable.
How is Next Science's financial position?
Financial Position Analysis
Short Term Liabilities: NXS's short term assets ($15.7M) exceed its short term liabilities ($1.6M).
Long Term Liabilities: NXS's short term assets ($15.7M) exceed its long term liabilities ($1.5M).
Debt to Equity History and Analysis
Debt Level: NXS is debt free.
Reducing Debt: NXS had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NXS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if NXS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Next Science current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NXS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NXS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NXS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NXS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NXS's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ms. Judith Mitchell, M.B.A, serves as Managing Director and Chief Executive Officer of Next Science Limited since August 2017 and serves as its Executive Director since October 20, 2017. Previously, Ms. Mi...
CEO Compensation Analysis
Compensation vs Market: Judith's total compensation ($USD277.24K) is below average for companies of similar size in the Australian market ($USD547.68K).
Compensation vs Earnings: Judith's compensation has been consistent with company performance over the past year.
Experienced Management: NXS's management team is considered experienced (3.3 years average tenure).
Experienced Board: NXS's board of directors are considered experienced (4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: NXS insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.9%.
Next Science Limited's employee growth, exchange listings and data sources
- Name: Next Science Limited
- Ticker: NXS
- Exchange: ASX
- Founded: 2012
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: AU$249.447m
- Shares outstanding: 197.97m
- Website: https://www.nextscience.com
- Next Science Limited
- The Zenith Building, Tower A
- Suite 1902
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/20 15:35|
|End of Day Share Price||2021/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.